Animol was founded by Andrew Calabrese, Andrew Calabrese, Ph.D. in 2018.

Who are Animol's investors?

Animol's investors include Novalis LifeSciences, Anterra Capital, DYDX Capital.

How much funding has Animol raised?

Animol has disclosed $36M raised across 2 rounds.

Where is Animol headquartered?

Animol is headquartered in Boston, US.

Animol

Boston, US · Founded 2018 · 3 known investors

Find your way into Animol

1,224 people in our graph share verified history with the Animol team — schools, employers, funds. One of them is your warm intro.

Rebecca Jamesunlockedknows Douglas E. Hutchens · together at The Wharton School (overlapped)

×4knows the team · via Harvard Business School

×2knows the team · via The Wharton School

knows the team · via 23andMe

×2knows the team · via Stanford University Graduate School of Business

knows the team · via Bayer Pharmaceuticals

Animol is a biopharmaceutical company developing a proprietary pipeline of novel veterinary small-molecule drugs for both companion and farm animals, targeting areas from anti-parasitics to chronic diseases. It uses a technology platform to discover active pharmaceutical ingredients designed for veterinary patients.

AgTech AI & Machine Learning Biotech Deep Tech Healthtech

Founders & leadership

Animol was founded in 2018 by Andrew Calabrese and Andrew Calabrese, Ph.D..

Andrew Calabrese inScientific Co-FounderInvestor at Anterra Capital

Andrew Calabrese, Ph.D.Scientific Co-Founder

Douglas E. Hutchens inCSOChief Scientific Officer of Animol, a biopharmaceutical company developing novel veterinary small-molecule drugs. Hutchens has experience in animal health research and development, drug development, and regulatory affairs across international teams.

Logan Andrews inHead of Program ManagementLogan Andrews is Head of Program Management at Animol, a biopharmaceutical company developing veterinary small-molecule drugs. He has a background in biology.

Philip Austin inManaging Partner, Anterra Capital; co-founder of AnimolManaging Partner and Co-Founder at Anterra Capital

Andrew PlantinChief Executive Officer2022–2023Investor at Animol Discovery, Inc.

Board

Marijn DekkersBoard directorChairman at Novalis LifeSciences

Michelle Haven inBoard directorVenture Partner at Anterra Capital

Investors · 3

Novalis LifeSciences✓ verifiedPortsmouth

Anterra Capital✓ verifiedAmsterdam · $20M

DYDX CapitalRedwood City

Reported raises · per SEC filings

Form D private placements

$36M disclosed across 2 rounds · 2022–2024

▶$4MraisedDec 2024 · 1 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Marijn DekkersDirector
Michelle HavenDirector
Philip AustinExecutive Officer, Director

Offering amount: $4M
Amount sold: $4M
First sale: Nov 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$32MraisedAug 2022 · 3 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Michelle HavenDirector
Philip AustinExecutive Officer, Director
Andrew PlantExecutive Officer, Director
Marijn DekkersDirector

Offering amount: $32M
Amount sold: $32M
First sale: Jul 2022
Incorporated: Corporation, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Anivive Lifesciences3 shared keywordsAnivive develops new medicines for companion animals, using software across the drug development process to accelerate the creation of treatments. It serves the animal health community, focusing on veterinary and pet health pharmaceuticals.

Examol3 shared keywordsCloud infrastructure for computational chemistry.

Companies competing with Animol for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Animol do?: Animol is a biopharmaceutical company developing a proprietary pipeline of novel veterinary small-molecule drugs for both companion and farm animals, targeting areas from anti-parasitics to chronic diseases. It uses a technology platform to discover active pharmaceutical ingredients designed for veterinary patients.
Who founded Animol?: Animol was founded by Andrew Calabrese, Andrew Calabrese, Ph.D. in 2018.
Who are Animol's investors?: Animol's investors include Novalis LifeSciences, Anterra Capital, DYDX Capital.
How much funding has Animol raised?: Animol has disclosed $36M raised across 2 rounds.
Where is Animol headquartered?: Animol is headquartered in Boston, US.